Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Biosig Technologies is a medical devices business based in the US. Biosig Technologies shares (BSGM) are listed on the NASDAQ and all prices are listed in US Dollars. Biosig Technologies employs 50 staff and has a trailing 12-month revenue of around $159,000.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $1.14 |
|---|---|
| 52-week range | $0.25 - $1.49 |
| 50-day moving average | $1.05 |
| 200-day moving average | $0.75 |
| Wall St. target price | $4.17 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.73 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.14 from 2023-03-31
| 1 week (2023-03-24) | 1.79% |
|---|---|
| 1 month (2023-03-02) | 11.22% |
| 3 months (2022-12-30) | 171.43% |
| 6 months (2022-09-30) | 78.13% |
| 1 year (2022-04-01) | -2.56% |
|---|---|
| 2 years (2021-04-01) | -74.55% |
| 3 years (2020-04-02) | 3.61 |
| 5 years (2018-03-29) | 3.925 |
| Revenue TTM | $159,000 |
|---|---|
| Gross profit TTM | $242,000 |
| Return on assets TTM | -137.08% |
| Return on equity TTM | -283.86% |
| Profit margin | 0% |
| Book value | $0.04 |
| Market capitalisation | $69.7 million |
TTM: trailing 12 months
We're not expecting Biosig Technologies to pay a dividend over the next 12 months.
Biosig Technologies's shares were split on a 2:5 basis on 10 September 2018. So if you had owned 5 shares the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Biosig Technologies shares – just the quantity. However, indirectly, the new 150% higher share price could have impacted the market appetite for Biosig Technologies shares which in turn could have impacted Biosig Technologies's share price.
Over the last 12 months, Biosig Technologies's shares have ranged in value from as little as $0.251 up to $1.49. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biosig Technologies's is 1.3658. This would suggest that Biosig Technologies's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
BioSig Technologies, Inc. , together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.
The best trading apps come with low fees and are easy to use.
Here’s what happens to your securities if your brokerage fails, and how your assets are protected by SIPC and FDIC.
Learn about buying physical gold, plus stocks and ETFs, to learn how you can add gold exposure to your portfolio.
Several ETFs have exposure to Silicon Valley Bank, but it appears minimal.
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
The 16th largest US bank has collapsed, but its impact on your portfolio could be limited depending on what you own.
Steps to investing in the Vanguard (VTI) Total Stock Market ETF.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.